This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Buy National Vision (EYE) Stock Now
by Zacks Equity Research
Investors are optimistic about National Vision (EYE) backed by its improvement in comparable store sales (comps) in eyeglasses and contact lens.
Integra (IART) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cantel (CMD) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Cantel (CMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Retain AmerisourceBergen (ABC) Stock
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako and broad product portfolio. However, pricing pressure raises a concern.
Veeva Systems (VEEV) Inks Deal to Advance Clinical Trials
by Zacks Equity Research
Veeva Systems (VEEV) collaborates with Parexel to accelerate clinical trials by combining the best of each company's experience.
Integra (IART) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Integra (IART) is optimistic about maintaining its strength in its international business, along with its portfolio optimization strategy.
Walgreens (WBA) Inks Deal to Expand COVID-19 Testing Access
by Zacks Equity Research
Walgreens' (WBA) recent deal with Abbott is part of its ongoing efforts to offer greater testing access, helping reduce the spread of COVID-19 and improve the health of communities.
Thermo Fisher (TMO) to Expand in Pharma Service With PPD Buyout
by Zacks Equity Research
Thermo Fisher's (TMO) $17.4-billion acquisition deal will offer the company meaningful cost and revenue synergies.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about STERIS (STE) backed by elevated consumer demand and strong segmental growth in third-quarter fiscal 2021.
Globus Medical (GMED) Simplifies Spine Surgery With CREO ONE
by Zacks Equity Research
Globus Medical's (GMED) latest development to robotically navigated spine surgery will enable surgeons to maintain the navigational accuracy without performing traditional pedicle preparation.
Medtronic (MDT) Boosts Diabetes Management via New Infusion Set
by Zacks Equity Research
Medtronic's (MDT) recently introduced Medtronic Extended infusion set with longer wearability enhances convenience and comfort, thus improving diabetes care.
Amedisys (AMED) Inks Deal to Extend Home Health Care Operations
by Zacks Equity Research
Amedisys' (AMED) new agreement to acquire Randolph Country regulatory assets will broaden the company's footprint in the Home Health care market.
Here's Why You Should Hold on to NEOGEN (NEOG) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.
Bruker Corporation (BRKR) Reports Solid Preliminary Q1 Revenues
by Zacks Equity Research
Bruker's (BRKR) revenue improvement in the first quarter is likely to have been boosted by robust performance by all three of its BSI groups.
PRA Health (PRAH) Chosen by MedChi to Offer Telehealth Services
by Zacks Equity Research
PRA Health's (PRAH) company, Care Innovations, gets selected by MedChi to provide remote patient monitoring services, thereby enabling better patient care.
Walgreens (WBA) Extends COVID-19 Vaccination to 49 States
by Zacks Equity Research
Walgreens (WBA) continues to expand access to COVID-19 vaccination in medically underserved communities and has surpassed 11 million administrations to date.
Reasons to Hold on to Align Technology (ALGN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Align Technology (ALGN) on solid customer adoption of Invisalign and iTero products.
Luminex (LMNX) to Get Acquired by DiaSorin for Around $1.8B
by Zacks Equity Research
Luminex (LMNX) to be acquired by DiaSorin for around $1.8 billion. This is likely to advance its technology and solutions' foothold outside the United States.
Here's Why You Should Hold on to Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio.
Here's Why You Should Hold on to STERIS (STE) Stock Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) owing to strong segmental performance amid the pandemic and huge growth potential in healthcare and pharmaceutical industries.
Abbott (ABT) Gets Europe Nod for TriClip G4 to Treat TR
by Zacks Equity Research
Per Abbott's (ABT) TRILUMINATE CE Mark study, the latest version shows sustained symptomatic improvement, reduction in the severity of TR and improvement in functional status.
Here's Why You Should Hold on to McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Varian (VAR) Inks Deal With Google Cloud to Boost Cancer Care
by Zacks Equity Research
Varian (VAR) partners with Google Cloud to help in the fight against cancer through the development of an advanced AI based diagnostic platform.
Cardinal Health (CAH) Unveils Navista TS to Boost Patient Care
by Zacks Equity Research
Cardinal Health (CAH) Specialty Solutions' newly launched Navista TS will help community oncologists to improve patient care and become successful in value-based care while reducing costs.